Pitcairn Co. Buys 19,750 Shares of Novo Nordisk A/S $NVO

Pitcairn Co. grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 159.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,113 shares of the company’s stock after acquiring an additional 19,750 shares during the period. Pitcairn Co.’s holdings in Novo Nordisk A/S were worth $1,782,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. SG Americas Securities LLC raised its holdings in shares of Novo Nordisk A/S by 2,101.5% in the 3rd quarter. SG Americas Securities LLC now owns 2,383,176 shares of the company’s stock worth $132,242,000 after purchasing an additional 2,274,925 shares during the period. DAVENPORT & Co LLC increased its position in Novo Nordisk A/S by 54.8% in the third quarter. DAVENPORT & Co LLC now owns 2,642,498 shares of the company’s stock worth $146,644,000 after buying an additional 935,468 shares during the last quarter. Sustainable Growth Advisers LP increased its position in Novo Nordisk A/S by 11.7% in the second quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after buying an additional 649,390 shares during the last quarter. Baird Financial Group Inc. raised its stake in shares of Novo Nordisk A/S by 42.6% in the second quarter. Baird Financial Group Inc. now owns 1,476,673 shares of the company’s stock valued at $101,920,000 after buying an additional 441,034 shares during the period. Finally, Holocene Advisors LP bought a new stake in shares of Novo Nordisk A/S in the second quarter valued at $25,745,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NYSE:NVO opened at $38.60 on Friday. Novo Nordisk A/S has a 52-week low of $35.85 and a 52-week high of $88.55. The business’s fifty day moving average is $51.41 and its 200 day moving average is $52.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm has a market cap of $172.35 billion, a price-to-earnings ratio of 11.12 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to analysts’ expectations of $11.97 billion. Research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a dividend of $1.2751 per share. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is 23.63%.

Analysts Set New Price Targets

Several research firms have recently weighed in on NVO. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. CICC Research initiated coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 target price for the company. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, February 23rd. Five investment analysts have rated the stock with a Buy rating, seventeen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $53.93.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Morgan Stanley raised Novo Nordisk to Equal Weight, and related analyst chatter lifted the stock in earlier trading — a near-term supportive catalyst. Novo Nordisk A/S (NYSE:NVO) Raised to Equal Weight at Morgan Stanley
• Neutral Sentiment: General coverage and “trending” write-ups (Zacks/Yahoo) are driving retail attention but contain no new fundamental news; these pieces can increase volume/volatility without changing long‑term fundamentals. Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Be aware of ticker-noise: several press releases referencing “NVO” (Novo Resources, ASX: NVO) circulated today — these are not related to Novo Nordisk (NYSE:NVO) but can create confusion in scanners and newsfeeds. Completion of Tranche 1 of Placement and Valuation Update
• Negative Sentiment: Roche reported positive Phase II results for petrelintide (up to ~10.7% weight loss with good tolerability) and plans further development — new obesity competitors gaining efficacy/tolerability could pressure Novo Nordisk’s market share and growth expectations. Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
• Negative Sentiment: A study reporting generic Ozempic/Wegovy could be produced for under $3/month highlights potential long‑term pricing pressure and margin risk if cheaper biosimilars/generics scale globally. That raises erosion risk to high-margin GLP‑1 revenues. Generic Ozempic Could Cost Less Than $3 a Month, Study Shows
• Negative Sentiment: Regulatory scrutiny increased after the FDA issued (another) warning about marketing/ads for Ozempic/Wegovy — ongoing ad/regulatory issues could hurt promotion and patient uptake and lead to fines or stricter controls. FDA sends Novo Nordisk 2nd warning over GLP-1 ads
• Negative Sentiment: Pomerantz law firm announced an investigation into Novo Nordisk investor claims, which can increase legal uncertainty and weigh on sentiment until resolved. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S – NVO

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.